How do you know if a vaccine is safe and protects against COVID-19 ?
Text updated on 2021-07-22
Pre-clinical and then clinical trials (phase 1, 2 and 3) are used to evaluate the dosage, tolerance, potential toxicity, adverse effects, and efficacy of a vaccine. Then, once the vaccine has been granted marketing authorization, a pharmacovigilance phase begins to monitor the tolerance and efficacy of the vaccine under real-life conditions of use.
A vaccine must go through several phases of development.
First ofall, pre-clinical (animal)testing is usually carried out on rodents and then on monkeys. This is an essential step to select the best candidates and avoid giving humans vaccines that are ineffective or that would cause too many inflammatory reactions. These trials can often give excellent results in animals, but not necessarily in humans.
Next, clinical trials are conducted in humans. In the case of COVID-19, tens of thousands of people have volunteered for these clinical trials to determine if the vaccine is safe and effective. These trials include people from diverse racial and ethnic backgrounds, of different sexes and ages, possibly with a variety of chronic health problems (co-morbidities). Clinical trials have four stages.
Phase I is the phase that evaluates the ideal dose and can provide a first glimpse of the potential toxicity of the vaccine. It is carried out on a few dozen volunteers to ensure that the vaccine is safe and does not cause severe adverse effects. Several dosages are tested. In addition, the nature of the immune response stimulated by the vaccine (level of neutralizing antibodies) is carefully analyzed.
The second clinical phase, or Phase II, is the phase that sometimes allows for refining the dosage, continuing to evaluate adverse events and, most importantly, having some idea of the vaccine's effectiveness in humans. It is carried out on a larger sample (several hundred to several thousand people) and makes it possible to verify that the vaccinated people produce the antibodies required to fight the disease. At this stage, the goal is not necessarily to measure the rate of protection provided by the vaccine, but it can be done.
Phase III is used to evaluate the tolerance andefficacy of the vaccine. In the context of COVID-19, it is usually conducted on 20 to 50,000 volunteers in real-life conditions. Volunteers are distributed randomly: either in the group of those who will receive the vaccine, or in the "control" group of those who will receive a placebo (an injection not containing the vaccine). In order to avoid any bias, the volunteers and the therapists do not know what they are administering and therefore the patient does not know what he or she is receiving. This is the so-called "double-blind" procedure.
Then each person is followed up for several months to monitor their health. The length of follow-up depends on the frequency of the disease: it was very short for the Covid-19 because we were in a pandemic phase with a lot of virus circulating. The vaccinated group is then compared to the placebo group to see if the vaccine has an effect on the disease. COVID-19. All negative reactions to the vaccine, but also to the placebo, which usually occur in the days following the injections, are looked for and recorded. Volunteers are also observed in the long term to detect any other problems. These large-scale trials allow the detection of rare adverse events and the definition of which age groups or population groups the candidate vaccine is effective in.
Finally, phase IV trials, which follow the marketing authorisation of the vaccine, are carried out after the vaccine has been marketed to determine its use in populations that were not included in the phase II and III trials. This is a pharmacovigilance phase, to monitor the tolerance of the vaccine under real conditions of use and to answer questions such as the duration of the protection of the immune system after vaccination, the proportion of healthy carriers (can vaccinated people who have developed antibodies against the coronavirus still be infected and transmit the disease), etc.
The results of the trials are reviewed by experts independent of the companies that manufacture the vaccine and by government agencies and health authorities in each country.
COVID-19 vaccine trials started in 2020. These clinical trials mobilize more than 200,000 participants worldwide, a multitude of research teams and considerable resources, including in emerging countries such as India and Kazakhstan. According to the World Health Organization, more than 180 vaccines are currently being studied, but only a few have undergone clinical trials in non-human primates or humans.
Against COVID-19, at least six vaccines have been the subject of large phase III clinical trials (more than 10,000 participants): those of Pfizer/BioNTech, Moderna, AstraZeneca, Novavax, CureVac, Janssen/J&J, but also Chinese and Russian vaccines for which we have less data. Most of the ongoing Phase III studies are designed to achieve a protection rate of at least 50%, with prevention of mild to moderate forms of the disease as the primary efficacy endpoint. Mild to moderate forms are more frequent and earlier onset than severe forms, and thus provide a more rapid indication of vaccine efficacy than if severe forms had been analyzed. However, this approach raises questions in a context in which it is the severe forms that burden health care institutions. Only one of these Phase III trials (Janssen's Ad26.COV2.S vaccine) selected moderate to severe forms of COVID-19.
The different stages of vaccine development.https://www.infovac.ch/fr/faq/developpement-d-un-vaccin
The FDA's June 2020 recommendations on the development of a vaccine against COVID-19.Development and Licensure of Vaccines to Prevent COVID-19 - Guidance for Industry, June 2020
The FDA's October 2020 recommendations on the development of a vaccine against COVID-19.Preparatory documents for the meeting of the Vaccine Committee scheduled for October 22, 2020, at the FDA.
Article presenting the key points concerning the main vaccines developed against COVID-19.Korsia-Meffre, S.(2020). Vaccines against COVID-19 an update on the ongoing Phase III trials. Vidal. Article published on October 8, 2020.
Update on vaccines published on September 23, 2020 in the journal Nature.Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586(7830), 516-527.